Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
ConclusionsPSMA-TO-1 tumor uptake tended to be greater than that of PSMA-617 in both preclinical and clinical settings. Mice treated with225Ac-PSMA-TO-1 conferred a significant survival benefit compared to225Ac-PSMA-617 despite the accompanying increased kidney uptake. In humans, PSMA-TO-1 dosimetry estimates suggest increased tumor absorbed doses; however, the kidneys, salivary glands and bone marrow are also exposed to higher radiation doses. Thus, additional preclinical studies are needed before further clinical use.
Source: EJNMMI Research - Category: Radiology Source Type: research
More News: Cancer | Cancer & Oncology | Prostate Cancer | Radiology | SPECT | Study | Urology & Nephrology